Why Are IUD and Contraceptive Implant Insertions Still Costing Patients Out-of-Pocket Under the ACA?

Privately insured patients are paying hundreds of dollars out-of-pocket for long-acting reversible contraception (LARC) insertions—despite the Affordable Care Act (ACA) requiring full coverage—according to a new KFF analysis published in Contraception. The study, funded by the David and Lucile Packard Foundation and conducted by researchers Linda Li, Brittni Frederiksen, and Alina Salganicoff, found that 28% of patients with employer-sponsored insurance reported unexpected expenses averaging $198 for IUD insertions and $123 for contraceptive implants in 2025. These costs violate federal mandates and create a significant access barrier for a method ranked most effective at preventing unintended pregnancies by the CDC.

Key Clinical Takeaways:

• 28% of privately insured patients with employer plans faced out-of-pocket costs for LARC insertions in 2025, despite ACA coverage requirements.
• Average unexpected expenses were $198 for IUDs and $123 for implants, driven by copays, deductibles, and provider billing errors.
• LARC methods remain the most effective contraceptive option (99% efficacy for IUDs, 99.95% for implants), yet cost barriers disproportionately affect low-income and young patients.

Why Are Patients Paying When the ACA Says They Shouldn’t?

The ACA’s contraceptive mandate, finalized in 2012, explicitly requires all private health plans to cover FDA-approved contraceptive methods—including LARC—without cost-sharing. Yet the KFF study identified three primary mechanisms driving patient expenses:

• Network exclusions: 18% of surveyed patients reported their insurance plan excluded the specific IUD or implant brand prescribed by their provider, forcing them to pay for a non-preferred alternative.
• Provider billing loopholes: 42% of unexpected charges stemmed from clinics billing patients directly for “facility fees” or “professional services” not covered by insurance, a practice increasingly scrutinized by the HHS Office for Civil Rights.
• Deductible timing: 35% of patients incurred costs because their plan’s annual deductible hadn’t been met at the time of insertion, despite the procedure being fully covered.

Dr. Sarah Roberts, director of the Bixby Center for Global Reproductive Health at UC San Francisco, notes that these gaps exploit “the fine print of insurance contracts.” Patients assume their insurance covers LARC, but the reality is that plan administrators often reclassify these as ‘elective’ procedures, delaying coverage until deductibles are satisfied. Roberts’ team documented similar patterns in a 2024 study published in JAMA Network Open, where 22% of LARC users reported delayed care due to insurance denials.

How Do These Costs Compare to Other Contraceptive Methods?

The financial disparity between LARC and other contraceptive options is stark. According to the Guttmacher Institute’s 2025 cost analysis:

Dr. Daniel Grossman, professor of obstetrics and gynecology at UC San Francisco and co-author of the Contraception study, emphasizes that the cost burden falls disproportionately on patients who can least afford it: Young adults and low-income individuals are three times more likely to encounter these unexpected charges, creating a two-tiered system where effectiveness is priced out of reach for many. His research, funded by the National Institute of Child Health and Human Development (NICHD), found that patients earning below 200% of the federal poverty level were 40% more likely to abandon LARC due to cost concerns.

What’s Behind the Billing Errors—and How Are Providers Responding?

The KFF analysis traced the root cause to a combination of insurance plan design flaws and provider billing practices. A 2025 survey by the American College of Obstetricians and Gynecologists (ACOG) revealed that 68% of reproductive health clinics reported increasing administrative burdens to verify insurance coverage for LARC procedures. Clinics in states with Medicaid expansion saw a 25% reduction in unexpected charges, suggesting that state-level policies can mitigate the problem.

To address this, several provider networks are implementing pre-authorization protocols and patient advocacy programs. For example:

• [Planned Parenthood Health Centers] now offers a “Coverage Concierge” service to pre-screen insurance plans and appeal denials, reducing patient out-of-pocket costs by 30% in pilot programs.
• [Ob-Gyn clinics affiliated with the University of California Health system] have partnered with legal aid organizations to challenge insurance denials, resulting in a 45% success rate in overturning facility fee charges.
• [Reproductive health compliance attorneys, such as those at Reproductive Legal Defense Fund, are advising clinics on how to navigate the ACA’s non-discrimination provisions when plans exclude specific LARC brands.

Dr. Jennifer Conti, medical director of the Bixby Center, warns that the issue extends beyond individual clinics: The problem is systemic. Insurance companies are increasingly using LARC as a ‘loss leader’—offering it as a covered benefit to attract patients, then nickel-and-diming them on the details. This undermines the entire purpose of the ACA mandate.

What Happens Next? Regulatory and Clinical Pathways

The KFF findings come as the Biden administration has signaled renewed enforcement of the ACA’s contraceptive coverage rules. In May 2026, the HHS Office for Civil Rights issued a new guidance memo clarifying that plans cannot impose copays or deductibles on LARC procedures. However, compliance remains uneven.

For patients already facing unexpected costs, the next steps depend on their specific situation:

• Appeal the charge: Patients should request an itemized bill and dispute any fees labeled as “facility” or “professional services” not covered by their plan. [CFPB’s health insurance complaint portal] can assist with formal appeals.
• Switch providers: Clinics participating in the ACOG’s ACA Compliance Network guarantee zero out-of-pocket costs for LARC insertions.
• Advocate for policy change: State-level organizations like [The National Women’s Law Center] are pushing for legislation to cap LARC costs at $0, citing California’s successful model where similar laws reduced patient expenses by 90%.

On the clinical side, providers are increasingly adopting bundled billing models to simplify reimbursement. For instance, [Everlywell’s reproductive health clinic network] has eliminated facility fees entirely by contracting directly with insurers at a flat rate, ensuring patients pay nothing at the point of service.

The Bigger Picture: Why LARC Access Matters Beyond Cost

Beyond the financial burden, the KFF study highlights a broader equity gap in contraceptive access. LARC methods are particularly critical for:

• Teenagers: The CDC reports that 82% of teen pregnancies are unintended, yet adolescents are the most likely to encounter LARC cost barriers due to their reliance on employer-sponsored plans.
• Patients with chronic conditions: Women with conditions like endometriosis or PCOS often require LARC for both contraception and symptom management, yet their complex care needs increase the likelihood of insurance denials.
• Rural populations: A 2025 study in Health Affairs found that rural clinics are 30% less likely to offer LARC due to reimbursement challenges, exacerbating disparities in reproductive healthcare.

Dr. Rachel Jones, senior research scientist at the Guttmacher Institute, frames the issue in terms of public health morbidity: When patients avoid LARC due to cost, we see a direct increase in unintended pregnancies, abortions, and maternal complications. The data shows that for every 10% reduction in LARC access, we see a 7% rise in teen birth rates within two years.

What Providers and Clinics Need to Know Now

The KFF analysis serves as a wake-up call for healthcare providers to audit their billing practices and insurance contracts. Key actions include:

• Audit insurance contracts: Verify that all LARC brands are included in your plan’s formulary. [Healthcare compliance attorneys, such as those at McGuireWoods Consulting, specialize in reviewing these agreements to ensure ACA compliance.]
• Implement pre-authorization checks: Use tools like [Waystar’s revenue cycle management software] to flag potential denials before patients incur costs.
• Educate patients on their rights: Partner with organizations like [The Reproductive Health Access Project] to provide patients with step-by-step guides for appealing insurance denials.

For patients already affected, the most immediate solution may be to seek care at clinics that have optimized their billing processes. [Planned Parenthood’s “Zero Cost” LARC program], for example, has processed over 50,000 insertions with zero out-of-pocket costs since 2024 by leveraging direct contracts with insurers.

Looking Ahead: Will the Problem Worsen or Improve?

Projections from the Kaiser Family Foundation suggest that without intervention, the problem will persist—or even grow—as more insurers adopt high-deductible plans. However, three developments could shift the trajectory:

• Federal enforcement: The HHS guidance issued in May 2026 is a critical step, but its effectiveness depends on state attorneys general taking action. [California’s Department of Managed Health Care] is already investigating insurers for violations, setting a precedent for other states.
• Legislative fixes: The Access to Contraception Act, reintroduced in 2026, would eliminate all cost-sharing for contraception, including LARC. If passed, it would resolve the issue at the federal level.
• Provider innovation: Telemedicine platforms like [Nurx] and [Hers] are expanding LARC access by offering same-day insertions with guaranteed insurance coverage, though their long-term sustainability depends on insurer partnerships.

Dr. Li, lead author of the KFF study, remains cautiously optimistic: This isn’t just a billing issue—it’s a public health crisis. The good news is that we already have the tools to fix it: stronger enforcement, better provider education, and patient advocacy. The question is whether the political will matches the clinical need.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.